Drug intelligence / Profile preview

enalapril + folic acid + amlodipine

Development stage
Unknown
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral
01

Overview

Enalapril + folic acid + amlodipine is a fixed-dose combination drug containing three active ingredients: - **Enalapril** is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion. - **Folic acid** (vitamin B9) is included for its ability to lower plasma homocysteine levels, which are associated with increased cardiovascular risk. Folic acid supplementation in hypertensive patients with hyperhomocysteinemia has been shown to further reduce the risk of stroke and cardiovascular events when combined with antihypertensive therapy. - **Amlodipine** is a dihydropyridine calcium channel blocker that reduces blood pressure by inhibiting calcium influx into vascular smooth muscle cells, resulting in vasodilation. This combination targets both hypertension and elevated homocysteine levels, conditions that synergistically increase the risk of stroke and other cardiovascular events. Clinical studies have demonstrated that combining these agents can provide additive or synergistic effects on lowering blood pressure and reducing total homocysteine concentrations compared to monotherapy or dual combinations[1][2][3]. The combination may be particularly beneficial for patients who require comprehensive management of hypertension complicated by hyperhomocysteinemia.

Other names
enalapril + amlodipine + folic acidenalapril maleate + amlodipine besylate + folic acid
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ACE (Angiotensin Converting Enzyme)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on enalapril + folic acid + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enalapril + folic acid + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call